Reddy’s Will Look For Acquisitions Under New CEO Israeli
Executive Summary
With Erez Israeli set to step up from COO to CEO, Dr Reddy’s is looking to leverage its lack of debt and strong cash flow in the mergers and acquisitions arena.
You may also be interested in...
Dr Reddy’s Debuts US Vimovo Rival At Risk
Dr Reddy’s has announced the launch of the first US generic version of Vimovo delayed-release tablets. However, Nuvo has warned that the at-risk launch infringes patents protecting the arthritis pain treatment until May 2022.
Dr Reddy’s Posts Surprise Q3 Loss With NuvaRing Write-Off
Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge related to its generic version of the NuvaRing contraceptive. However, the company’s shares jumped on a robust underlying performance that was praised by analysts.
Dr Reddy’s Posts Surprise Q3 Loss But Strong Operating Results Boost Shares
Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge for its generic NuvaRing contraceptive but the company’s shares jumped on a robust underlying performance that analysts praised as a "great set of numbers."